Breast cancer is one of the major cause of mortality among women in both the developed and developing world. Early detection remains the primary defense available to patients in preventing the development of life-threatening breast cancer. Breast cancer screening is the regular examination of a woman's breasts to find breast cancer early. Screening for breast cancer primarily involves mammography. It is the best screening test for reducing the risk of dying from breast cancer. In addition to mammography, the screening method such as MRI and ultrasound may be used to help find breast cancer in young women with a high risk for developing breast cancer.
The global breast cancer screening market is anticipated to grow over the forecasting period. The major factors driving the market for breast cancer screening are growing incidence of breast cancer globally, increasing government initiatives and support, rising female geriatric population base, increasing awareness about early detection of breast cancer, and technological advancements. However, factors such as controversies related to mammography and socio-cultural barriers are expected to restrain the growth of this market in the coming years.
Breast Cancer Screening Market and Population Analysis: United States is the largest market for breast cancer screening. Germany and China are the second and third leading market for breast cancer screening and are competing closely with each other to grab maximum share of the pie. United Kingdom is the fourth largest market for breast cancer screening holding XX% share in 2015 being followed by Italy with XX% market share. Spain and France accounted for XX% and XX% share of the global breast cancer screening market respectively in 2015.
In terms of breast cancer screening population, the countries such as United States, China, Japan, Germany and United Kingdom captures maximum share of the pie. In 2015, these five countries together accounted for over 60% share of the global breast cancer screening population. Brazil, Spain, Italy, France, South Korea and India are the other top contributors to the global breast cancer screening population.
iGATE RESEARCH report titled “Breast Cancer Screening (Mammography, MRI and Ultrasound) Market and Population Forecast to 2021 - Global Analysis” is a 510 Page report with 448 Figures and 16 Tables. This report provides a comprehensive assessment of the breast cancer mammography, MRI and ultrasound screening market in terms of value and volume.
All the 31 countries covered in the report have been analyzed from 7 viewpoints:
1. Breast Cancer Screening Population, Market and Forecast 2. Breast Cancer Mammography Screening Population and Forecast 3. Breast Cancer MRI and Ultrasound Screening Population and Forecast 4. Breast Cancer Mammography Screening Market and Forecast 5. Breast Cancer MRI Screening Market and Forecast 6. Breast Cancer Ultrasound Screening Market and Forecast 7. Global Breast Cancer Screening Market - Drivers and Challenges
Breast Cancer Screening Market and Population Forecast - 31 Countries Covered
1. United States 2. Canada 3. United Kingdom 4. Germany 5. France 6. Spain 7. Italy 8. Switzerland 9. Norway 10. Netherlands 11. Czech Republic 12. Denmark 13. Estonia 14. Finland 15. Hungary 16. Iceland 17. Ireland 18. Slovakia 19. Slovenia 20. Israel 21. Japan 22. South Korea 23. China 24. India 25. Singapore 26. Malaysia 27. Thailand 28. Australia 29. New Zealand 30. Brazil 31. Mexico
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
Our reports have been used by over 10K customers, including:
533 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Oct 2018
Diagnostic imaging is a non-invasive method for identifying and monitoring diseases or injuries by generating the images of internal anatomic structures and organs of the body for diagnosis purpose. It is used for the diagnosis of the most life threatening diseases such as cancer and heart disease and has nearly eliminated...
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 18.104.22.168) - Pipeline Review, H2 2018 Summary Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 22.214.171.124) - Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2....
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary According to the recently published report ’SerineThreonine Protein Kinase Pim 3 - Pipeline Review, H2 2018’; Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 188.8.131.52)...
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 220.127.116.11) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase...
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2018 Summary Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)...
Bone Metastasis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape. Bone metastasis occurs when cancer cells...
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2018 Summary Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes...